Project Grant 2507639
Award Date
6/15/25
Completion Date
5/31/26
Dollars Obligated
$305K
Federal Agency
National Science Foundation
Federal Grant Program
47.084
Assistance Type
Project Grant
Place of Performance
Washington, DC 20002, USA
Similar Awards
This $275,000 Small Business Technology Transfer (STTR) Phase I grant from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships program) was awarded to Oncoblaze LLC to develop a novel device for targeted delivery of chemotherapy agents to tissue surrounding surgically removed tumors. The project aims to address the issue of tumor recurrence after cancer surgery, which affects 30-40% of patients for certain cancers. The device uses an infrared laser to heat...
This $275,000 federal Project Grant award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program supports the development of Illuminate Therapeutics' Light Activated Drug Delivery and Release (LADDR) platform technology. The LADDR platform aims to enable precise spatiotemporal delivery of small therapeutic RNAs to tumors in head and neck and esophageal cancers, with the goal of preserving healthy tissues and reducing side effects compared to...
This federal Project Grant award of $374,095 from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), aims to develop a device that uses an infrared laser to enable local delivery of a high dose of chemotherapy to the surgical cavity after tumor resection. The technology employs thermosensitive liposomal nanoparticles encapsulating chemotherapy agents that...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Cerflux Inc. aims to develop a personalized cancer treatment screening platform. The project will establish guidelines for handling solid tumor biopsy samples, generate 3D bioprinted tumor models for validation, and demonstrate the platform's ability to match patients with the most effective cancer treatments before treatment begins. This innovative approach has the...
This STTR Phase I project, funded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084), aims to advance the development and evaluation of a hand-held induction heater device for treating pancreatic and prostate cancer using magnetic fluid hyperthermia (MFH) technology. The project, awarded to Ihnnova LLC, a small business located in Guánica, Puerto Rico, will receive $275,000 in funding over the period of October 1, 2024 to...
This Cooperative Agreement awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program provides $1,213,619.00 to Encapsulate Inc., a small disadvantaged business, to develop a precision oncology platform that integrates microfluidics, biochips, bioreactors, and 3D tumor models to predict patient-specific cancer drug responses. The project aims to create tumor models from patient-derived biopsy specimens, allowing oncologists to test...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $305,000 to Redpoint Oncology, Inc. aims to develop and validate a novel platform for targeted cancer therapies. The project will design and synthesize new "payload" candidates, test their effectiveness and selectivity against therapy-resistant cancer cells, and establish proof-of-concept for this innovative therapeutic approach, which functions similarly to guided...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $274,999 to Therafluor Inc. aims to develop a low-cost multimodal medical instrument for use in veterinary clinics. The instrument will visualize, monitor, and enable the targeted delivery of a proprietary photosensitive compound (silicon naphthalocyanine nanoparticles) to detect and eliminate cancer cells in companion animals. The project seeks to create a new diagnostic and...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $274,990 to Eascra Biotech, Inc. aims to develop a regulatory pathway for commercializing space-made Janus Base Nanoparticles (JBNPs) as an innovative drug delivery system for treating solid tumors. The project focuses on demonstrating the comparability of space-manufactured JBNPs to earth-made counterparts, which is a crucial step for the commercialization of space-made...
This $274,594 Project Grant award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program supports research and development of an innovative technology for cancer diagnosis and treatment. The project aims to improve molecular profiling and clinical laboratory testing of cancer samples by optimizing microdissection techniques. The research will focus on modeling and optimizing the opto-thermal-mechanical interactions involved in microdissection to...